Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05452941 · ClinicalTrials.gov registry record
A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting
A clinical trial of Pneumonia, sponsored by Pfizer.
- Recruiting
- Registry status
- 12,500
- Enrollment target
- 20
- Study locations
NCT05452941: Recruiting study of Pneumonia, sponsored by Pfizer.
NCT05452941 is a study of Pneumonia that is actively recruiting participants, run by Pfizer. The registered enrollment target is 12,500 participants, above the 4,254-participant average among 47 other Pneumonia trials with a reported enrollment target (194% higher). The trial reports 20 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05452941, a study of Pneumonia, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- 12,500 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to learn about how well the 20-valent pneumococcal conjugate vaccine (20vPnC) works against radiologically-confirmed community-acquired pneumonia (RAD+CAP) due to the 7 new serotypes (types of a bacteria called Streptococcus pneumoniae that cause pneumonia) included in 20vPnC vaccine. This study is seeking participants who: * are male or female ≥65 years of age. * are hospitalized with physician suspicion of community acquired pneumonia (CAP). * have pneumonia confirmed with imaging like a chest x-ray Participants will be asked to provide demographic and medical history information, and to provide a urine sample that will be used to test for pneumonia caused by specific strains of a bacteria called Streptococcus pneumoniae. We will compare the proportion of participants who have pneumonia caused by specific strains of the bacteria Streptococcus pneumoniae and were previously vaccinated with 20vPnC with the proportion of participants who have pneumonia caused by something other than vaccine type Streptococcus pneumoniae and have been vaccinated with 20vPnC. Participants will actively take part in the study for about 1-2 days. Information on participant's illness and hospitalization details will be collected through day 30 of their hospitalization through medical chart review.
Primary Outcome
Vaccine effectiveness as calculated as 1 minus the odds ratio for 20vPnC vaccination among cases vs. controls multiplied by 100 adjusted for potentially confounding variables
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Diagnostic test on urine samples
Study Locations (20)
California
- Kaiser Permanete Baldwin Park - Baldwin Park
- Kaiser Permanete Downey - Downey
- El Centro Regional Medical Center - El Centro
- Kaiser Permanente Fontana Medical Center - Fontana
- University of California San Francisco - Fresno - Fresno
- Kaiser Permanente Los Angeles Medical Center - Los Angeles
- Kaiser Permanente - Los Angeles
- Kaiser Permanente West Los Angeles Medical Center - Los Angeles
- Kaiser Permanente Vaccine Study Center - Oakland
- Kaiser Permanente Oakland Medical Center - Oakland
- Kaiser Permanente Ontario Medical - Ontario
- Southern California Permanente Medical Group (SCPMG) - Pasadena
- Kaiser Permanente Riverside Medical Center - Riverside
- Kaiser Permanente Roseville Medical Center - Roseville
- Kaiser Permanente South Sacramento Medical Center - Sacramento
- Kaiser Permanente Sacramento Medical Center - Sacramento
- Kaiser Permanente Zion Medical Center - San Diego
- Kaiser Permanente San Diego Medical Center - San Diego
- Kaiser Permanente San Jose Medical Center - San Jose
- Kaiser Permanente Santa Clara Medical Center - Santa Clara
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12,500 participants |
| Start Date | 2022-10-27 |
| Est. Completion | 2027-06-04 |
What NCT05452941 shows while recruiting
NCT05452941 is an observational study that tracks outcomes without assigning an intervention. Its 12,500 participants enrollment target places it among the larger protocols in the corpus, above the 4,254-participant average among 47 other Pneumonia trials with a reported enrollment target (194% higher).
The record links to 1 condition, with Pneumonia appearing as the primary indexed condition, and to 1 intervention - of which Diagnostic test on urine samples is the first listed.
NCT05452941 names 20 study sites across 1 states, led by California.
Frequently Asked Questions
What is clinical trial NCT05452941 about?
NCT05452941 is a clinical study titled "A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting". The purpose of this study is to learn about how well the 20-valent pneumococcal conjugate vaccine (20vPnC) works against radiologically-confirmed community-acquired pneumonia (RAD+CAP) due to the 7 new serotypes (types of a bacteria called Streptococcus pneumoniae that cause pneumonia) included in 2...
What is the current status of trial NCT05452941?
This trial is currently recruiting. The enrollment target is 12,500 participants. The study started on 2022-10-27. Estimated completion is 2027-06-04.
What conditions does trial NCT05452941 study?
This clinical trial studies the following conditions: Pneumonia.
What interventions are being tested in trial NCT05452941?
The interventions under investigation include: Diagnostic test on urine samples (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05452941?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05452941 being conducted?
This trial has 20 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pneumonia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05452941's enrollment target sits among peer trials
12,500 4th of 47 higher than 44 of 47 other Pneumonia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pneumonia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The APS Phenotyping Study
RECRUITING
-
Reducing Overuse of Antibiotics With Decision Support
RECRUITING · NA
-
Extending Dental Care to Nursing Home Residents to Reduce Mouth Infections and Incidence of Pneumonia and Improve Diabetic Glucose Control
RECRUITING · NA
-
Clinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU
RECRUITING · NA
-
Follow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial
RECRUITING · NA
-
How OMT Benefits Newly Diagnosed Patients With Respiratory Illness When Given Alongside Other Standard Care.
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04888832 · 12,500 participants · NA
The Effect of Work Requirements in SNAP in Virginia
- NCT07069556 · 12,500 participants
ColoSense Post-Approval Study
- NCT07037433 · 12,800 participants · Phase 3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- NCT03586895 · 12,838 participants · NA
e-Connect: A Service System Intervention for Justice Youth at Risk for Suicide
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI